10β-(3'-morpholinopropoxy)dihydroartemisinin

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 10β-(3'-morpholinopropoxy)dihydroartemisinin
• 英文别名: 1-morpholino-3-(10β-dihydroartemisinoxy)propane；4-[3-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]propyl]morpholine
• 化学式: C₂₂H₃₇NO₆
• 分子量: 411.539
• InChiKey: WNVSXJGVUNAZFC-MCGYWDJFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  58.6
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  dihydroartemisinin 在 三氟化硼乙醚 作用下， 以 1,4-二氧六环 、 乙醚 为溶剂， 反应 6.0h， 生成 10β-(3'-morpholinopropoxy)dihydroartemisinin
  参考文献：
  名称：

  双氢青蒿素 - 10-α 青蒿琥酯的 C-10 酯和醚衍生物、正宗 10-β 青蒿琥酯的制备以及在 C-10 处具有潜在芳族插入基团的其他酯和醚衍生物的制备

  摘要：

  已经检查了提供抗疟药双氢青蒿素 (DHA, 2) 的新 C-10 酯和醚衍生物的反应的制备和立体化学方面。β-青蒿琥酯首次制备，与抗疟药α-青蒿琥酯相鉴别；后者在化学文摘和一些主要文献中被错误地指定为 β-差向异构体。通过 Schmidt、Mitsunobu 和 DCC 偶联程序、在 DMAP 存在下的酰化或以 BF3 作为催化剂的羟基活化，已经合成了带有潜在嵌入基团的新酯和醚衍生物。当 DHA 的羟基对酰化剂或 DCC 中间体中的活化羧基充当亲核试剂时，只能获得 α-酯。当羟基被激活以被亲核试剂取代时，如在 Schmidt 或 Mitsunobu 程序中，β-酯和 β-醚被完全或主要获得。一个例外是涉及 DHA 和 1- 和 2-萘酚的 Mitsunobu 程序，其中获得差向异构体的混合物；然而，当使用 Schmidt 程序时，会发生 β-芳基醚的独家形成，中间体三氯乙酰亚胺被 SnCl2

  DOI：

  10.1002/1099-0690(20021)2002:1<113::aid-ejoc113>3.0.co;2-n

文献信息

• Synthesis and Antimalarial Activity of Artemisinin Derivatives Containing an Amino Group
  作者：Ying Li、Yuan-Ming Zhu、Hong-Jian Jiang、Jian-Ping Pan、Guang-Shao Wu、Jin-Ming Wu、Yun-Lin Shi、Jun-De Yang、Bo-An Wu

  DOI：10.1021/jm990552w

  日期：2000.4.1

  In search of water-soluble artemisinin derivatives that are more stable than sodium artesunate, over 30 derivatives containing an amino group (compounds 3-5) were synthesized and tested in mice. All products tested (except 5a and 5b) are the beta isomers. These basic compounds combined with organic acids (oxalic acid, maleic acid, etc.) to yield the corresponding salts. Generally, the maleates have better solubility in water than the corresponding oxalates. The aqueous solutions of these salts can be kept at room temperature for several weeks without any discernible decomposition. Compounds 3f, 3h, and 3r are much more active against P. berghei than artesunic acid by oral administration and therefore were further tested in monkeys. However, their oral efficacies are poorer than that of artesunic acid against P. knowlesi in rhesus monkeys. It is interesting to note that 3f, 3h, and 3r showed much lower efficacies against P. berghei when they were administered subcutaneously than orally.
• C-10 Ester and Ether Derivatives of Dihydroartemisinin − 10-α Artesunate, Preparation of Authentic 10-β Artesunate, and of Other Ester and Ether Derivatives Bearing Potential Aromatic Intercalating Groups at C-10
  作者：Richard K. Haynes、Ho-Wai Chan、Man-Ki Cheung、Wai-Lun Lam、May-Kei Soo、Hing-Wo Tsang、Arnd Voerste、Ian D. Williams

  DOI：10.1002/1099-0690(20021)2002:1<113::aid-ejoc113>3.0.co;2-n

  日期：2002.1

  providing new C-10 ester and ether derivatives of the antimalarial drug dihydroartemisinin (DHA, 2) have been examined. β-Artesunate has been prepared for the first time, and has been differentiated from the antimalarial α-artesunate; the latter has been incorrectly designated as the β-epimer in Chemical Abstracts and some primary literature. New ester and ether derivatives bearing potential intercalating

  已经检查了提供抗疟药双氢青蒿素 (DHA, 2) 的新 C-10 酯和醚衍生物的反应的制备和立体化学方面。β-青蒿琥酯首次制备，与抗疟药α-青蒿琥酯相鉴别；后者在化学文摘和一些主要文献中被错误地指定为 β-差向异构体。通过 Schmidt、Mitsunobu 和 DCC 偶联程序、在 DMAP 存在下的酰化或以 BF3 作为催化剂的羟基活化，已经合成了带有潜在嵌入基团的新酯和醚衍生物。当 DHA 的羟基对酰化剂或 DCC 中间体中的活化羧基充当亲核试剂时，只能获得 α-酯。当羟基被激活以被亲核试剂取代时，如在 Schmidt 或 Mitsunobu 程序中，β-酯和 β-醚被完全或主要获得。一个例外是涉及 DHA 和 1- 和 2-萘酚的 Mitsunobu 程序，其中获得差向异构体的混合物；然而，当使用 Schmidt 程序时，会发生 β-芳基醚的独家形成，中间体三氯乙酰亚胺被 SnCl2